Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › nervous system diseases

Nervous system diseases

Subtypes of Nervous system diseases

Neurological disorders 14

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for nervous system diseases

20 trials tracked for nervous system diseases: 8 in phase 3 or 4 and 5 with published results. The most-cited published study has 452 citations.

20Trials tracked
8Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 8 Phase 2 3 Phase 1 1 Other / NA 8
  1. Phase 3 Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Completed · 452 cited
  2. Phase 3 Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Completed · 14 cited
  3. Phase 3 Topical Vancomycin for Neurosurgery Wound Prophylaxis Completed · 9 cited
  4. Phase 3 A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation Completed · 2 cited
  5. Phase 3 Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy Completed · 1 cited
  6. Phase 3 Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan Completed
Show 14 more trials
  1. Phase 3 Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting Completed
  2. Phase 3 A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia Completed
  3. Phase 2 AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed
  4. Phase 2 Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole Completed
  5. Phase 2 A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Completed
  6. Phase 1 Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia Completed
  7. N/A Predictors of Response in Chronic Stroke Completed
  8. N/A Long-term Telerehabilitation for Patients With Stroke Completed
  9. N/A Dietary Supplements for the Treatment of Angelman Syndrome Completed
  10. N/A GORE Flow Reversal System and GORE Embolic Filter Extension Study Completed
  11. N/A Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers Completed
  12. N/A Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus Completed
  13. N/A Cost-effectiveness of Forced Aerobic Exercise for Stroke Rehabilitation Completed
  14. N/A Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Nervous system diseases: what the trials found

New evidence indicates that Ataluren showed a statistically significant reduction in 6-Minute Walk Distance (6MWD) at week 72 when analyzed using an Intent-to-Treat (ITT) population 1. However, this same metric did not reach statistical significance in the Modified Intention-to-Treat (mITT) population 1. In a separate study of Ataluren, no significant change was observed in 6MWD at week 48 2.

Regarding agitation management, Brexpiprazole combined with OPC-34712 demonstrated a statistically significant reduction in the Cohen-Mansfield Agitation Inventory (CMAI) total score after 12 weeks of treatment 5, though it did not significantly impact Clinical Global Impression-Severity of Illness (CGI-S) scores related to agitation 5. A different trial using the same combination did not reach statistical significance for CMAI scores 3.

In the management of seizures, SHP615 demonstrated a response rate of 80% in a small cohort 8. In this study, patients showed sustained absence of seizure activity for at least 1, 4, and 6 hours at rates of 68.0%, 36.0%, and 32.0%, respectively 8. A smaller trial reported that no participants required additional anticonvulsant medication for ongoing status epilepticus after administration of SHP615 7.

For fibromyalgia, TNX-102 SL (2.8mg) showed a reduction in both the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score and Function Domain Score at week 12 6.

Recent results — preliminary, needs further review

  • Aerobic exercise was evaluated for motor function; results showed mean scores of 2.4 and 2.7 on the Wolf Motor Function Test (WMFT) 13.

For the clinician treating this condition

  • Ataluren shows mixed evidence regarding its impact on 6MWD, with significance only observed in ITT analysis 1.
  • Brexpiprazole combined with OPC-34712 significantly reduces Cohen-Mansfield Agitation Inventory (CMAI) scores in some instances but not all [3, 5].
  • SHP615 demonstrated a high response rate and sustained absence of seizure activity in patients with status epilepticus 8.
  • TNX-102 SL (2.8mg) is associated with improvements in both symptom and function domains for fibromyalgia 6.

AI synthesis of 8 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of UK Biobank data identifies plasma protein mediators in cardiometabolic disease progression
Diabetes & Endocrinology
Review of UK Biobank data identifies plasma protein mediators in cardiometabolic disease progression New Blood Test Clues Could Predict Diabetes Complications Years Earlier
This observational review analyzes UK Biobank data from 53,030 participants to evaluate plasma proteins as mediators in secondary disease de…
A new blood test spots specific proteins that warn of heart, kidney, and brain problems years before they happen in people with diabetes or …
medRxiv Apr 19, 2026
Video consultations reduced symptom burden in palliative neurological care compared to treatment as usual
Palliative Care Cohort
Video consultations reduced symptom burden in palliative neurological care compared to treatment as usual Video calls bring brain specialists to home care
This prospective, partly-cluster-randomized, two-arm intervention study with a delayed-start design enrolled 114 patients with neurological …
A simple video call can instantly connect struggling patients with brain specialists, making their care feel more complete and less lonely.
Frontiers Apr 16, 2026
Higher physical activity volume associated with lower risk of incident nervous system diseases in UK Biobank participants
Neurology Cohort
Higher physical activity volume associated with lower risk of incident nervous system diseases in UK Biobank participants Moving More May Protect Your Brain and Nerves
This retrospective cohort study analyzed 278,306 UK Biobank participants to evaluate the association between physical activity volume and in…
Getting more exercise could significantly lower your chances of developing conditions that affect your nerves and brain.
Frontiers Apr 10, 2026
Review examines automated ventricular segmentation from MRI for neurological disease insights
Neurology Sys. Review
Review examines automated ventricular segmentation from MRI for neurological disease insights Review examines automated brain ventricle measurement tools for neurological disease research
A systematic review describes applications of automated ventricular segmentation techniques from brain MRI compared to manual methods.
Better automated tools now help researchers understand how brain diseases develop in both adults and children using MRI scans.
Frontiers Apr 2, 2026